Low dose IL-2 administration prevents but fails to treat experimental autoimmune anti-myeloperoxidase glomerulonephritis
In experimental anti-MPO GN, low dose IL-2 therapy has context specific effects on cellular and humoral immunity, and the potential for it to promote T effector responses in established autoimmunity may limit its utility in this condition.
Authors
- Jonathan Dick (ORCID: https://orcid.org/0000-0003-4012-9610)
- Joshua D. Ooi (ORCID: https://orcid.org/0000-0003-3328-2561)
- Anne Cao Le
- A. Richard Kitching (ORCID: https://orcid.org/0000-0002-2713-2391)
- Kei Nagai (ORCID: https://orcid.org/0000-0001-5050-5291)
- Maliha A. Alikhan (ORCID: https://orcid.org/0000-0002-2578-3457)
- Daniel Koo Yuk Cheong
- Poh‐Yi Gan (ORCID: https://orcid.org/0000-0001-8373-7144)
- Julie A. Monk (ORCID: https://orcid.org/0000-0002-9926-6102)
- Diana Shu Yee Tan (ORCID: https://orcid.org/0009-0001-1684-3454)
Institutions
- University of Tsukuba (JP)
- Monash Medical Centre (AU)
- University of Tsukuba Hospital (JP)
- Monash Health (AU)
- Monash University (AU)
Publication Details
- Journal
- Nephrology Dialysis Transplantation
- Published
- 2025-08-28
- DOI
- https://doi.org/10.1093/ndt/gfaf178
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Monash University
- Medical Research Council
- National Health and Medical Research Council